CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss FDA scrutiny over Whoop's blood pressure monitoring tech.
Breakdown
- FDA sent Whoop a warning letter over its blood pressure monitoring feature.
- FDA alleges the feature is being marketed without proper regulatory approval. 4s
- Whoop claims the feature offers wellness insights and is protected by the 21st Century Cures Act. 25s
- FDA argues the feature could be used to diagnose or treat disease, requiring medical device approval. 42s
- Whoop has 15 days to respond, and the case could set a precedent for wearable tech regulation. 1m 12s